Hairy Cell Leukemia

🗣️:🇺🇲/👥: 👨‍⚕️🩸🦀 🤔 Peripheral flow cytometry for a possibility of firstly hairy cell leukemia and than marginal zone lymphoma. Bone marrow Asp&biopsy for BRAF mutation, and further differantiate possible causes. If one of them watch & wait might be a rational solution. (@Dr_MSU)

Path finals, gross specimen identification station. Examiner: Please identify (points at a teratoma) Candidate: I don't know. Examiner: What's this? (points at hair) Candidate: Hair Examiner: So, what's the specimen likely to be? Candidate: 💡 Hairy cell leukaemia Examiner: 🤦🏽‍♂️ (@ashwinrajenesh)

Response rate to vemurafenib in refractory hairy cell leukemia was 96 to 100 percent; NEJM Tiacci et al, 2015 :) (@Dr_R_Kurzrock)

BRAF mutation Seen in melanoma (40-60%) papillary thyroid carcinoma (45%), colonic adenocarcinoma (10-15%), hairy cell leukemia (~100%) lung adenocarcinoma, epithelioid glioblastoma, and hematologic malignancies, including hairy cell leukemia, LCH, ECD (@Sthanu5)

Oncology master level board review! What do the following malignancies all have in common? @Dr_R_Kurzrock Mandibular ameloblastoma Hairy cell leukemia Melanoma Erdheim Chester disease Papillary thyroid cancer (@AaronGoodman33)

Hairy cell leukemia (@DrRichaJuneja)

Hairy cell leukemia? (@PEPPS_CK)

hairy cell leukemia (@notjordanianspy)

Hairy cell leukemia (@Macchiato1986)

Hairy cell leukaemia ( fried egg appearances) . (@NancyDaffodils)

This study in @BloodJournal showed activity in BRAF + Hairy cell leukemia 6/10👉 Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @OncoAlert @weoncologists cc @AaronGoodman33 @Dr_R_Kurzrock @doctorpemm… https://t.co/7iLu5vEswR (@VivekSubbiah)

Hairy Cell Leukemia #HCLsm for the win! 89% response. Interestingly, only 91% of HCL patients in the trial were confirmed BRAF V600E positive. Wonder if the other 9% were non-HCL such as the new WHO classification Splenic B-cell lymphoma/leukaemia with prominent nucleoli #AACR23 (@TaylorJ_MD)

Hairy cell leukemia. B-RAF mutated (@RamonGarciaSanz)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/QswEGQHTDu (@VivekSubbiah)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/QswEGQHTDu (@VivekSubbiah)

⚡️Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @BloodJournal @OncoAlert https://t.co/QswEGQHTDu (@VivekSubbiah)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @BloodJournal https://t.co/QswEGQHTDu (@VivekSubbiah)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/uvTHFV1Z9q dual targeted therapy for RR HCL. 2 yrs OS up to 95%. (@TalhaBadarMD)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia | Blood | American Society of Hematology https://t.co/pPrHvlQhm5 (@SCTNB)

Mycobacteria. Pancytopenia, potentially signifying bone marrow failure Warts. R/O GATA2 R/O hairy cell leukemia (although HPV not known to be an issue with HCL, and age is too young) (@DonaldVinh)

BRAF mutations are seen in up to 10% of various cancers - melanoma (40–60%), thyroid cancer (50%), glioma (11%), colorectal ca (10%), cholangiocarcinoma (6%), non-small cell lung carcinoma (NSCLC) (3%), hairy cell leukemia, multiple myeloma, and Langerhans cell histiocytosis (@VivekSubbiah)

BRAF-negative, CD103-negative hairy cell leukemia https://t.co/BNfKcBTk6S (@smbenlazar)

Excellent review on BRAF alterations and medication targeting #targetedtherapy #cancer #cancers #melanoma #lungcancer #coloncancer #thyroidcancer #hairycellleukemia #nonhodgkinslymphoma #ovariancancer #braintumors #Erdheimchesterdisease #hepatobiliarycancer (@sejadiMD)

Hairy cell leukemia. The presence of 3 or 4 of the following markers; CD11c, CD103, CD123, and CD25, is observed in almost all cases of classic HCL. The variant form of HCL now corresponds to splenic B-cell lymphoma/leukemia with prominent nucleoli. (@DavidGa34100783)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia @ASH_hematology https://t.co/Xa44VAPjR7 (@VivekSubbiah)

And thanks to Dr. Claire Dearden for the editorial: It’s a BRAF new world for hairy cell leukemia https://t.co/QPZyrCtvl3 (@TaylorJ_MD)

It’s a BRAF new world for hairy cell leukemia #lymsm >>> Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy https://t.co/DTONN4Xord (@smbenlazar)

Six riddles for precision oncology Riddle #3: do mutations possess tissue tropism? Yes and no B-RAF V600E is everywhere— melanoma, hairy cell leukemia, lung Ca, etc Bcr-Abl is leukemia— but wait— GBM case (imatinib response): brain tumor didn’t read the books Need universal NGS! (@Dr_R_Kurzrock)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia @ASH_hematology @BloodJournal https://t.co/Xa44VAOM1z (@VivekSubbiah)

Blood smears @ASH_hematology 🧵Heme boards 🩸Malignant Hematopoietic Neoplasms🩸 #mmsm #lymsm #leusm #bmtsm 1⃣1⃣Hairy cell leukemia 🩸hairy cells👇 🩸CD11c+,CD22+,CD25+.CD103+ 🩸BRAF V600E mutation (@HadidiSamer)

Bone Marrow Fibrosis + Splenomegaly DDx! Primary myelofibrosis = JAK2/CALR/MPL Hairy cell leukemia = BRAF V600E TAFRO = Castleman dz subtype Gaucher = ⬇️glucocerebrosidase Kala-azar (visceral leishmania) Gray platelet = NBEAL2 AIDS Renal osteodystrophy Some CML (@AaronGoodman33)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia https://t.co/Xa44VB6mT7 (@VivekSubbiah)

⭐️Amazing week for #PrecisionMedicine 🎯Selpercatinib for RET fusion + cancers in @TheLancetOncol as tissue agnostic target 🎯 BRAF+ MEK combo in BRAF V600+ Hairy cell leukemia in https://t.co/WgpPaMxFLb @BloodJournal @OncoAlert @MDAndersonNews https://t.co/G0RCJ1x459 (@VivekSubbiah)

Amazing responses & outcomes in relapsed/ refractory BRAF + Hairy cell leukemias. Also Rituximab free regimen may be better in these COVID19 times. KM curves 👇🏼 (@VivekSubbiah)

⭐️🎯Just published 👉🏼My first publication in Blood & such a delight to work with hematology colleagues 👉🏼Dabrafenib + trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia #PrecisionMedicine @BloodJournal https://t.co/Xa44VAPjR7 (@VivekSubbiah)

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia https://t.co/Xa44VAPjR7 (@VivekSubbiah)

🚨⭐️🎯 Hot off the press @BloodJournal 🩸 ✅Dabrafenib+ trametinib in patients with relapsed/refractory BRAF V600E + hairy cell leukemia -ROAR 🦁 Trial @OncoAlert https://t.co/Xa44VAPjR7 (@VivekSubbiah)

BRAF Mutation hairycell leukaemia (@AlasfarLina)

Hairy cell leukemia - By Prunelle Getten (fellow in Internal Medicine, Paris, France) #leukemia #hairycell #BRAF #Internistacademy (@TerrierBen)

Mature B-cell Leukemias by CD5/CD10 CD5+/CD10-: CLL = CD23+ Leukemic mantle = CD23-, FMC7+ CD5-/CD10-: Hairy cell leukemia = CD123+, BRAF+ Hairy cell leukemia variant = CD123-, BRAF- SMZL LPL B-cell prolymphocytic leukemia = CD5+/-, TP53 CD5-/CD10+: Leukemic follicular cell (@AaronGoodman33)

1. Hairy cell leukaemia. 2. CD 25 and CD 103 (@QueenHeme)

Bone Marrow Fibrosis + Splenomegaly A fantastic DDx! Myelofibrosis = JAK2, CALR, MPL Hairy cell leukemia = BRAF V600E TAFRO = Castleman subtype Gaucher = ⬇️glucocerebrosidase Kala-azar (visceral leishmania) = parasite in sandfly Gray platelet = NBEAL2 AIDS Renal osteodystrophy (@AaronGoodman33)